Download Visit us at www.ipharmadirect.com

pg 1/2
March 18, 2009
DUCHESNAY RELEASES A COMPLETE PRODUCT
MONOGRAPH FOR PREGVIT/PREGVIT FOLIC 5
Duchesnay brings forward significant innovation by releasing the first
complete Product Monograph for the safe and effective use of
pre/postnatal supplements. The scientific literature reports many
examples of vitamin/mineral-drug interactions. For example, calcium and
iron interaction with thyroid hormone products such as levothyroxine has
been well documented.
In addition to showing a detailed description of product indications and
properties, the PregVit/PregVit folic 5 Product Monograph provides fully
referenced clinical trial data, drug interaction summary and individualized
dosing and administration information.
PregVit/PregVit folic 5 Product Monograph is available on
http://monograph.pregvit.com. To receive a paper copy, send an e-mail
to: [email protected].
PregVit® and PregVit folic 5® are available at all wholesalers.
PRODUCTS
DIN
UPC
PregVit®
02246067
7 79943 00021
PregVit folic 5®
02276194
7 79943 00061
Pr
Pr
Duchesnay: 1.888.666.0611 ([email protected])
NEORAL*(CYCLOSPORINE)
10 MG, 25 MG, 50 MG, 100 MG CAPSULES
FREE CLASSIFIED ADVERTISING FOR PHARMACISTS
FAX :
1-800-420-3616
EMAIL:
[email protected]
Effective mid-February 2009, Novartis Pharmaceuticals Canada Inc. will
be implementing changes to the appearance of all Neoral capsule
strengths. The current “S” embedded in a triangle marking will be
replaced with an updated “NVR” marking. This change is expected to be
fully implemented for all strengths by May 2009.
This change only affects the capsule appearance and does not
affect either the formulation, capsule size, packaging and/or
product label/prescribing information. For any questions concerning
this change or correspondence, please contact Novartis Pharmaceuticals
Canada Inc. Medical Information at 1-800-363-8883.
Pr
Neoral*
Cyclosporine Capsules
10 mg
25 mg
50 mg
100 mg
*Neoral is a registered trademark.
© Novartis Pharmaceuticals Canada Inc.
Visit us at
www.ipharmadirect.com
DIN
02237671
02150689
02150662
02150670
pg 2/2
March 18, 2009
ZYBAN® UPDATE
COMBIGAN 10ML OPHTHALMIC SOLUTION
CONTINUES TO BE AVAILABLE FOR ORDERING
Combigan 10mL ophthalmic solution continues to be available for
ordering.
The price per ml remains unchanged for the 10mL. Combigan 10mL is
fully covered under all provincial formulary plans.
Although Combigan 5mL is unavailable, it is recommended that you
order Combigan 10mL ophthalmic solution.
Product
UPC
PM#
Combigan 10 mL ophthalmic Solution 0 69886-92112 0 92112EC
Should you require further information, please do not hesitate
to contact our Customer Service at 1-800-668-6477.
FREE CLASSIFIED ADVERTISING
FOR PHARMACISTS/
GRATUITS POUR PHARMACIENS
L’ÉCHANGE PHARMACIEN À PHARMACIEN®
FAX / TÉLÉCOPIEUR SANS FRAIS:
1-800-420-3616
EMAIL / COURRIEL:
The seizure rate associated with doses of bupropion SR up to 300
mg/day is approximately 0.1%. Please refer to the Zyban® Product
Monograph for complete dosing information.
CATEGORY / CATÉGORIE
•
•
•
•
•
There are clinical trials and post-marketing reports with SSRIs and other
newer anti-depressants, in both pediatrics and adults, of severe agitationtype adverse events coupled with self-harm or harm to others. The
agitation-type events include: akathisia, agitation, disinhibition, emotional
lability, hostility, aggression, depersonalization. In some cases, the events
occurred within several weeks of starting treatment. Given that bupropion
may be prescribed as either an anti-depressant (Wellbutrin®
SR/Wellbutrin® XL) or a smoking cessation product (Zyban®), these
findings affect the conditions of use of all these products.1
Agitation-type changes are reported for Zyban®, and monitoring for these
indicators of potential suicidal behaviour is advised in patients of all ages
given a newer anti-depressant drug, including bupropion. When reported
in patients undergoing a smoking cessation attempt, such changes may
be a symptom of nicotine withdrawal, along with depressed mood and
related symptoms, such as difficulty concentrating and anxiety.1
[email protected]
•
•
•
•
The most commonly observed adverse events in patients treated with
Zyban® are dry mouth (11%, compared with 5% in patients taking
placebo) and insomnia (31% vs. 21% with placebo). The risk of insomnia
may be reduced by avoiding bedtime doses.1
Career Opportunities / Perspectives de carrière
Pharmacy for Sale / Pharmacie à vendre
Pharmacy Wanted / Pharmacie demandée
For Sale - Pharmacy Store/Equipment / À vendre
- Équipement de pharmacie
Pharmacist Available / Pharmacien - disponible
Vacation Spots / Endroits de vacances
Seminars / Courses / Conférences et séminaires
For Sale - Miscellaneous / À vendre - divers
Other / Autre
Flexible to maximize patient sample
initiations
Offers multiple formats to leverage any
promotion
Guarantees a return on investment
Lowers the cost of delivering patient
samples
Increases the safety and integrity of your
drug samples
Extends the reach beyond your current
target physicians
The most recent version of the Zyban® Product Monograph is available
upon request.
Should you have any questions, please call Biovail Medical Information
at 1-866-825-8120 or e-mail us at [email protected].
References:
1 Zyban® (bupropion HCl) Product Monograph, Biovail Pharmaceuticals Canada, February 2009.
Pharmacist Information
Biovail Pharmaceuticals Canada would like to ensure that patients who
are prescribed Zyban® (bupropion hydrochloride) for smoking cessation
receive the most up-to-date information pertaining to the safety and
tolerability of this medication, in accordance with the recently updated
Product Monograph.
What topics would you like to see covered
in potential future editorial stories?
•
•
•
•
•
•
•
•
Reducing your taxes
Managing staff
Store security
Privacy laws
Internet dispensing
Consumer counseling
Inventory management
CHE requirements
________
________
________
________
________
________
________
________
Please fax to: 1-800-420-3616